GE Healthcare Technologies (GEHC) said Tuesday it has entered into a joint development initiative with Raydiant Oximetry to progress fetal oxygen saturation monitoring technology.
The collaboration aims to integrate Raydiant Oximetry's fetal pulse oximetry technology into GE HealthCare's fetal monitoring and digital perinatal surveillance platforms, with the goal of enhancing the detection of fetal distress during childbirth, GE Healthcare said.
Terms of the agreement were not disclosed.
GE Healthcare shares were 1.1% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.